Bundibugyo Ebola Outbreak Surges in Eastern Congo, Death Toll Tops 1,700

The Ebola outbreak in eastern Congo is expanding at an alarming pace. STAT and the Associated Press report that Bundibugyo Ebola virus has caused 3,802 recorded cases and 1,707 deaths. With no approved vaccine or specific treatment available, medical teams must not only try to save patients but also trace contacts and interrupt transmission amid conflict and displacement.

These latest totals stand in stark contrast to the World Health Organization’s figures from July 15. At that time, WHO had recorded 2,124 confirmed cases and 828 deaths in the Democratic Republic of the Congo, with the outbreak affecting 46 health zones across five provinces; Ituri Province accounted for nearly 90% of confirmed cases. Because the two datasets may have different cutoff dates and case classifications, the difference cannot be taken directly as the number of new cases; however, the overall trend clearly shows that transmission has not yet been brought under control.

The obstacles to containing the outbreak extend beyond the virus itself. WHO says armed conflict, security incidents, population movements, and inadequate health services are hindering investigations and contact tracing. In some areas, authorities cannot fully identify people who have had contact with patients, increasing the possibility of missed diagnoses and undetected transmission. WHO rates the risk within Congo as “very high,” while the current global risk remains low.

Bundibugyo virus is one of the orthoebolaviruses that can cause Ebola disease. Its incubation period is approximately 2 to 21 days, and patients are generally infectious only after symptoms appear. It can spread through contact with a patient’s blood or bodily fluids, contaminated objects, or unsafe burial practices. Early symptoms such as fever, fatigue, and muscle pain can also be easily confused with common febrile illnesses such as malaria, making rapid testing and isolation especially important.

The treatment gap has also made the ongoing PARTNERS trial in Congo more urgent. The study plans to enroll 700 to 1,000 patients within six months and compare standard supportive care, the MBP134 antibody combination alone, the antiviral drug remdesivir alone, and a combination of the two drugs. Effectiveness will be assessed primarily by mortality 28 days after treatment begins. These therapies remain experimental and cannot yet be regarded as proven effective.

Another study, the EBO-PEP trial, moves intervention to before the onset of illness. Since July 14, the study has been enrolling nearly 1,000 asymptomatic adults and children aged 12 years and older who experienced high-risk exposure within the previous five days, to assess whether the oral antiviral drug obeldesivir can be used as post-exposure prophylaxis. Participants will be followed daily for 21 days and undergo a final assessment on day 42. Because existing safety data are insufficient, children under 12, pregnant women, and breastfeeding people are being covered under a separate plan for compassionate use of remdesivir.

Candidate vaccine studies in Canada and the United Kingdom have likewise accelerated as the outbreak has worsened, but clinical evidence is still needed to determine whether they can generate an immune response sufficient to protect people. For now, the most reliable defenses remain rapidly identifying and isolating cases, providing comprehensive supportive care, implementing safe burials, and tracing contacts. Trials of new drugs and vaccines will determine whether healthcare workers have genuinely effective additional tools when confronting this rare virus in the future.